The company said net sales for Q1 2025 were $10,358 million, up 4.0% on a reported basis from $9,964 million a year earlier, and rose 6.9% on an organic basis.

1. 01

   The company said net sales for Q1 2025 were $10,358 million, up 4.0% on a reported basis from $9,964 million a year earlier, and rose 6.9% on an organic basis.

2. 02

   Abbott reported operating earnings of $1,693 million for Q1 2025, up 22.1%. It said diluted earnings per share were $0.76 on a GAAP basis and $1.09 excluding specified items. The company said income taxes included an adjustment of about $200 million related to the prior recognition of a significant non-cash deferred tax benefit.

3. 03

   The company said Medical Devices sales rose 9.9% on a reported basis in Q1 2025, while Diagnostics sales fell 7.2% on a reported basis. It cited the year-over-year decline in COVID-19 testing-related sales and volume-based procurement programs in China as factors affecting Diagnostics sales growth.

4. 04

   The company said it reaffirmed all previously provided full-year 2025 guidance, projecting organic sales growth of 7.5% to 8.5%, full-year adjusted diluted EPS of $5.05 to $5.25, and adjusted diluted EPS for Q2 of $1.23 to $1.27.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.